MCID: KPS004
MIFTS: 66

Kaposi Sarcoma malady

Categories: Genetic diseases, Rare diseases, Cancer diseases, Neuronal diseases

Aliases & Classifications for Kaposi Sarcoma

About this section
Sources:
45NIH Rare Diseases, 49OMIM, 10Disease Ontology, 47Novoseek, 51Orphanet, 65UMLS, 12DISEASES, 35MedlinePlus, 11diseasecard, 36MeSH, 27ICD10, 29ICD9CM, 42NCIt, 59SNOMED-CT, 28ICD10 via Orphanet, 37MESH via Orphanet, 66UMLS via Orphanet, 61The Human Phenotype Ontology
See all MalaCards sources

Aliases & Descriptions for Kaposi Sarcoma:

Name: Kaposi Sarcoma 49 10 45 47 51 65
Kaposi's Sarcoma 10 45 12 35
Kaposi's Sarcoma of Soft Tissue 10 65
Kaposi's Sarcoma of Palate 10 65
Kaposi's Sarcoma of Lung 10 65
Kaposi's Sarcoma of Central Nervous System 10
Kaposi's Sarcoma of Gastrointestinal Sites 10
African Lymphadenopathic Kaposi's Sarcoma 10
Kaposi's Sarcoma-Associated Herpesvirus 10
Central Nervous System Kaposi's Sarcoma 10
Kaposi's Sarcoma of the Gallbladder 10
Lymphadenopathic Kaposi's Sarcoma 10
Kaposi Sarcoma, Susceptibility to 11
Kaposi's Sarcoma of Soft Tissues 10
Kaposi's Sarcoma of the Prostate 10
Non Aids Related Kaposi Sarcoma 45
Non-Aids-Related Kaposi Sarcoma 65
Kaposi's Sarcoma of Conjunctiva 10
Kaposi's Sarcoma of Lymph Nodes 10
Kaposi's Sarcoma of Esophagus 10
Conjunctival Kaposi's Sarcoma 10
Soft Tissue Kaposi's Sarcoma 10
Gallbladder Kaposi's Sarcoma 10
Mediterranean Kaposi Sarcoma 45
Lymph Node Kaposi's Sarcoma 10
 
Intestinal Kaposi's Sarcoma 10
Esophageal Kaposi's Sarcoma 10
Kaposi's Sarcoma of the Cns 10
Kaposi Sarcoma Herpesvirus 45
Cutaneous Kaposi's Sarcoma 10
Kaposi's Sarcoma of Cornea 10
Pulmonary Kaposi's Sarcoma 10
Kaposi's Sarcoma of Heart 10
Kaposi's Sarcoma of Penis 10
Prostate Kaposi's Sarcoma 10
Kaposi's Sarcoma of Anus 10
Kaposi's Sarcoma of Skin 10
Gastric Kaposi's Sarcoma 10
Cardiac Kaposi's Sarcoma 10
Corneal Kaposi's Sarcoma 10
Palate Kaposi's Sarcoma 10
Penis Kaposi's Sarcoma 10
Kaposi's Sarcoma, Lung 10
Kaposi's Sarcoma, Skin 10
Anal Kaposi's Sarcoma 10
Human Herpesvirus 8 45
Sarcoma, Kaposi 36
Kshv 45
Hhv8 45

Characteristics:

Orphanet epidemiological data:

51
kaposi sarcoma:
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),1-9/100000 (Europe); Age of onset: Adult; Age of death: adult

HPO:

61
kaposi sarcoma:
Inheritance: autosomal dominant inheritance


Classifications:

Orphanet: 51 
Rare tumors


External Ids:

OMIM49 148000
Disease Ontology10 DOID:8632
MeSH36 D012514
Orphanet51 33276
ICD10 via Orphanet28 C46.0, C46.1, C46.2 C46.3, C46.7, C46.8, C46.9, more
MESH via Orphanet37 D012514
UMLS via Orphanet66 C0036220
UMLS65 C0036220, C0153560, C0153561 C0153562, C0153563, C0153564, C0153565, C0346935, C0346936, C1332265, C1332847, C1333453, C1333744, C1333776, C1334318, C1334457, C1335372, C1335509, C2974202, more

Summaries for Kaposi Sarcoma

About this section
NIH Rare Diseases:45 Kaposi sarcoma (ks) is a cancer that develops from the cells that line lymph or blood vessels. it usually appears as tumors on the skin or on mucosal surfaces such as inside the mouth, but tumors can also develop in other parts of the body (including the lymph nodes, lungs, or digestive tract). the abnormal cells of kaposi sarcoma cause purplish, reddish blue, or dark brown/black skin lesions (macules, nodules, plaques) on the legs and the face. these lesions may look bad, but they usually cause no symptoms. however, when the lesions are in the lungs, liver, or digestive tract, they may cause serious problems like gastrointestinal bleeding or trouble breathing. kaposi sarcoma is caused by infection with a virus called the kaposi sarcoma associated herpesvirus (kshv), also known as human herpesvirus 8 (hhv8). kaposi sarcoma is classified into four types based upon the different populations in which it develops: classic (which presents in middle or old age), endemic (described in sub-saharan indigenous africans), iatrogenic (associated with immunosuppressive drug therapy) and aids-associated (epidemic ks). options for treatment may include local therapy, radiation therapy, chemotherapy and biologic therapy (immunotherapy). the main aim is to restore immunity. last updated: 2/4/2016

MalaCards based summary: Kaposi Sarcoma, also known as kaposi's sarcoma, is related to dyskeratosis congenita and hepatocellular carcinoma, and has symptoms including hepatomegaly, splenomegaly and chest pain. An important gene associated with Kaposi Sarcoma is IL6 (Interleukin 6), and among its related pathways are Interferon Pathway and all-trans-Retinoic Acid Mediated Apoptosis. The drugs etoposide and etoposide phosphate have been mentioned in the context of this disorder. Affiliated tissues include skin, lung and lymph node, and related mouse phenotypes are liver/biliary system and tumorigenesis.

Disease Ontology:10 A connective tissue cancer that derives from lymphatic endothelium, and derives from spindle cells, results in formation of vascular channels that fill with blood cells, has material basis in Human herpesvirus 8 (HHV8).

OMIM:49 Kaposi sarcoma (KS) is an invasive angioproliferative inflammatory condition that occurs commonly in men infected with... (148000) more...

MedlinePlus:35 Kaposi's sarcoma is a cancer that causes patches of abnormal tissue to grow under the skin, in the lining of the mouth, nose, and throat or in other organs. the patches are usually red or purple and are made of cancer cells and blood cells. the red and purple patches often cause no symptoms, though they may be painful. if the cancer spreads to the digestive tract or lungs, bleeding can result. lung tumors can make breathing hard. before the hiv/aids epidemic, ks usually developed slowly. in hiv/aids patients, though, the disease moves quickly. treatment depends on where the lesions are and how bad they are. treatment for hiv itself can shrink the lesions. however, treating ks does not improve survival from hiv/aids itself. nih: national cancer institute

Related Diseases for Kaposi Sarcoma

About this section

Diseases related to Kaposi Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 265)
idRelated DiseaseScoreTop Affiliating Genes
1dyskeratosis congenita30.7FLT4, KDR, VEGFA
2hepatocellular carcinoma30.3CD34, FGF2, HGF, IFNA1, IFNA2, KDR
3endemic kaposi sarcoma12.6
4colon kaposi sarcoma12.5
5kshv inflammatory cytokine syndrome12.3
6human herpesvirus 811.8
7rectum kaposi's sarcoma11.5
8combined immunodeficiency due to ox40 deficiency11.5
9immunodeficiency 1610.7
10lysosomal storage disease10.6IFNA1, IFNA2
11chancroid10.6IFNA1, IFNA2
12residual stage angle-closure glaucoma10.6FGF2, IL6, VEGFA
13subareolar duct papillomatosis10.6IFNA1, IFNA2
14inherited metabolic disorder10.6FGF2, KDR, VEGFA
15protein-energy malnutrition10.6FGF2, IL6, VEGFA
16saethre-chotzen syndrome10.6HGF, IL6
17osteogenesis imperfecta, type x10.6IL6, IL6R, IL6ST
18expressive language disorder10.6FGF2, KDR, VEGFA
19bladder urachal squamous cell carcinoma10.6KDR, VEGFA
20tufted hair folliculitis10.6FLT4, IFNA2
21hemiplegia alterans10.6FLT4, VEGFA
22seminal vesicle acute gonorrhea10.6FLT4, KDR, VEGFA
23viral gastritis10.5IFNA1, IFNA2, IL6
24hypothyroidism due to deficient transcription factors involved in pituitary development or function10.5CD34, KDR, VEGFA
25myoepithelial carcinoma10.5FLT4, IFNA2
26solitary osseous plasmacytoma10.5IL6, IL6R, VEGFA
27chronic venous leg ulcers10.5FGF2, HGF, VEGFA
28crohn's disease10.5HGF, IL6
29malignant conjunctiva melanoma10.5FGF2, FLT4, KDR, VEGFA
30chronic eosinophilic pneumonia10.5CD34, IFNA1, IFNA2
31cell type benign neoplasm10.5CD34, IFNA1, IL6
32nezelof syndrome10.5CD34, TAT, VEGFA
33urethral diverticulum10.5IFNA1, IFNA2, IL6, TAT
34papillary serous adenocarcinoma10.5IFNA1, IFNA2, KDR, VEGFA
35citrullinemia, adult-onset type ii10.5FGF2, KDR, VEGFA
36cell type cancer10.5CD34, IFNA1, IL6, VEGFA
37catamenial pneumothorax10.5IL6, IL6R
38fuhrmann syndrome10.5HGF, KDR, VEGFA
39kaposi sarcoma10.5HGF, IL6
40macular degeneration, age-related, 110.5FGF2, IL6, KDR, VEGFA
41neuropathy, hereditary sensory and autonomic, type vi10.4FGF2, HGF, VEGFA
42blau syndrome10.4HGF, IL6
43neonatal stroke10.4CD34, FGF2, IFNA1, IFNA2
44bone remodeling disease10.4IFNA1, IL6, IL6R, IL6ST, VEGFA
45anterior foramen magnum meningioma10.4CD34, HGF
46ganglion or cyst of synovium/tendon/bursa10.4CD34, VEGFA
47chronic venous insufficiency10.4FGF2, HGF, IL6, KDR, VEGFA
48maculopapular lupus rash10.4IFNA1, IFNA2
49multicentric osteolysis nephropathy10.4IL6, IL6R
50cll/sll10.4CD34, IFNA1, IFNA2, IL6, TAT

Graphical network of the top 20 diseases related to Kaposi Sarcoma:



Diseases related to kaposi sarcoma

Symptoms for Kaposi Sarcoma

About this section

Symptoms by clinical synopsis from OMIM:

148000

Clinical features from OMIM:

148000

HPO human phenotypes related to Kaposi Sarcoma:

(show all 32)
id Description Frequency HPO Source Accession
1 hepatomegaly hallmark (90%) HP:0002240
2 splenomegaly hallmark (90%) HP:0001744
3 chest pain typical (50%) HP:0100749
4 abdominal pain typical (50%) HP:0002027
5 glomerulopathy occasional (7.5%) HP:0100820
6 erectile abnormalities occasional (7.5%) HP:0100639
7 abnormal immunoglobulin level occasional (7.5%) HP:0010701
8 peripheral neuropathy occasional (7.5%) HP:0009830
9 abnormal blistering of the skin occasional (7.5%) HP:0008066
10 generalized hyperpigmentation occasional (7.5%) HP:0007440
11 abnormality of temperature regulation occasional (7.5%) HP:0004370
12 lymphadenopathy occasional (7.5%) HP:0002716
13 abnormality of the pleura occasional (7.5%) HP:0002103
14 subcutaneous hemorrhage occasional (7.5%) HP:0001933
15 anemia occasional (7.5%) HP:0001903
16 thrombocytopenia occasional (7.5%) HP:0001873
17 weight loss occasional (7.5%) HP:0001824
18 ascites occasional (7.5%) HP:0001541
19 arthritis occasional (7.5%) HP:0001369
20 tapered finger occasional (7.5%) HP:0001182
21 lymphedema occasional (7.5%) HP:0001004
22 hypertrichosis occasional (7.5%) HP:0000998
23 skin rash occasional (7.5%) HP:0000988
24 secondary amenorrhea occasional (7.5%) HP:0000869
25 hypothyroidism occasional (7.5%) HP:0000821
26 diabetes mellitus occasional (7.5%) HP:0000819
27 gynecomastia occasional (7.5%) HP:0000771
28 proteinuria occasional (7.5%) HP:0000093
29 renal insufficiency occasional (7.5%) HP:0000083
30 neoplasm HP:0002664
31 hypermelanotic macule HP:0001034
32 edema HP:0000969

Drugs & Therapeutics for Kaposi Sarcoma

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)15 Company Approval Date
1
Doxil15 41 DOXORUBICIN HYDROCHLORIDE Alza June 1999
FDA Label: Doxil
Disease/s that Drug Treats:ovarian cancer that is refractory to other first-line therapies
Indications and Usage:15 DOXIL is an anthracycline topoisomerase II inhibitor indicated for: Ovarian cancer (1.1)After failure of platinum-based chemotherapy. AIDS-related Kaposi’s Sarcoma (1.2)After failure of prior systemic chemotherapy or intolerance to such therapy. Multiple Myeloma (1.3)In combination with bortezomib in patients who have not previouslyreceived bortezomib and have received at least one prior therapy.
DrugBank Targets:13 1. DNA;2. DNA topoisomerase 2-alpha
Mechanism of Action:15 
Target: nucleic acidsynthesis
Action: inhibitor
FDA: The active ingredient of DOXIL is doxorubicin HCl. The mechanism of action ofdoxorubicin HCl is thought to be related to its ability to bind DNA and inhibit nucleic acidsynthesis. Cell structure studies have demonstrated rapid cell penetration and perinuclearReference ID: 373359617 chromatin binding, rapid inhibition of mitotic activity and nucleic acid synthesis, andinduction of mutagenesis and chromosomal aberrations.
2
Intron A15 41 INTERFERON ALFA-2B Schering-Plough December 1997/ December 1995/ March 1997
FDA Label: Intron A
Disease/s that Drug Treats:non-Hodgkin's lymphoma/ malignant melanoma / Hepatitis C
Indications and Usage:15 Hairy Cell Leukemia INTRON® A is indicated for the treatment of patients 18 years ofage or older with hairy cell leukemia.Malignant Melanoma INTRON A is indicated as adjuvant to surgical treatment inpatients 18 years of age or older with malignant melanoma who are free of disease butat high risk for systemic recurrence, within 56 days of surgery.Follicular Lymphoma INTRON A is indicated for the initial treatment of clinicallyaggressive (see Clinical Pharmacology) follicular Non-Hodgkin’s Lymphoma inconjunction with anthracycline-containing combination chemotherapy in patients 18years of age or older. Efficacy of INTRON A therapy in patients with low-grade, lowtumorburden follicular Non-Hodgkin’s Lymphoma has not been demonstrated.Condylomata Acuminata INTRON A is indicated for intralesional treatment of selectedpatients 18 years of age or older with condylomata acuminata involving externalsurfaces of the genital and perianal areas (see DOSAGE AND ADMINISTRATION).The use of this product in adolescents has not been studied.AIDS-Related Kaposi's Sarcoma INTRON A is indicated for the treatment of selectedpatients 18 years of age or older with AIDS-Related Kaposi's Sarcoma. The likelihoodof response to INTRON A therapy is greater in patients who are without systemic symptoms, who have limited lymphadenopathy and who have a relatively intact immunesystem as indicated by total CD4 count.Chronic Hepatitis C INTRON A is indicated for the treatment of chronic hepatitis C inpatients 18 years of age or older with compensated liver disease who have a history ofblood or blood-product exposure and/or are HCV antibody positive. Studies in thesepatients demonstrated that INTRON A therapy can produce clinically meaningful effectson this disease, manifested by normalization of serum alanine aminotransferase (ALT)and reduction in liver necrosis and degeneration.A liver biopsy should be performed to establish the diagnosis of chronic hepatitis.Patients should be tested for the presence of antibody to HCV. Patients with othercauses of chronic hepatitis, including autoimmune hepatitis, should be excluded. Priorto initiation of INTRON A therapy, the physician should establish that the patient hascompensated liver disease. The following patient entrance criteria for compensated liverdisease were used in the clinical studies and should be considered before INTRON Atreatment of patients with chronic hepatitis C: No history of hepatic encephalopathy, variceal bleeding, ascites, or otherclinical signs of decompensation Bilirubin Less than or equal to 2 mg/dL Albumin Stable and within normal limits Prothrombin Time Less than 3 seconds prolonged WBC Greater than or equal to 3000/mm3 Platelets Greater than or equal to 70,000/mm3Serum creatinine should be normal or near normal.Prior to initiation of INTRON A therapy, CBC and platelet counts should beevaluated in order to establish baselines for monitoring potential toxicity. These testsshould be repeated at Weeks 1 and 2 following initiation of INTRON A therapy, andmonthly thereafter. Serum ALT should be evaluated at approximately 3-month intervalsto assess response to treatment (see DOSAGE AND ADMINISTRATION).Patients with preexisting thyroid abnormalities may be treated if thyroidstimulatinghormone (TSH) levels can be maintained in the normal range by medication.TSH levels must be within normal limits upon initiation of INTRON A treatment and TSHtesting should be repeated at 3 and 6 months (see PRECAUTIONS, LaboratoryTests).INTRON A in combination with REBETOL® is indicated for the treatment ofchronic hepatitis C in patients 3 years of age and older with compensated liver diseasepreviously untreated with alpha interferon therapy and in patients 18 years of age andolder who have relapsed following alpha interferon therapy. See REBETOL prescribinginformation for additional information. Chronic Hepatitis B INTRON A is indicated for the treatment of chronic hepatitis B inpatients 1 year of age or older with compensated liver disease. Patients who have beenserum HBsAg positive for at least 6 months and have evidence of HBV replication(serum HBeAg positive) with elevated serum ALT are candidates for treatment. Studiesin these patients demonstrated that INTRON A therapy can produce virologic remissionof this disease (loss of serum HBeAg) and normalization of serum aminotransferases.INTRON A therapy resulted in the loss of serum HBsAg in some responding patients.Prior to initiation of INTRON A therapy, it is recommended that a liver biopsy beperformed to establish the presence of chronic hepatitis and the extent of liver damage.The physician should establish that the patient has compensated liver disease. Thefollowing patient entrance criteria for compensated liver disease were used in theclinical studies and should be considered before INTRON A treatment of patients withchronic hepatitis B: No history of hepatic encephalopathy, variceal bleeding, ascites, or othersigns of clinical decompensation Bilirubin Normal Albumin Stable and within normal limits Prothrombin Time Adults less than 3 seconds prolongedPediatrics less than or equal to 2 seconds prolonged WBC Greater than or equal to 4000/mm3 Platelets Adults greater than or equal to 100,000/mm3Pediatrics greater than or equal to 150,000/mm3Patients with causes of chronic hepatitis other than chronic hepatitis B or chronichepatitis C should not be treated with INTRON A. CBC and platelet counts should beevaluated prior to initiation of INTRON A therapy in order to establish baselines formonitoring potential toxicity. These tests should be repeated at treatment Weeks 1, 2,4, 8, 12, and 16. Liver function tests, including serum ALT, albumin, and bilirubin,should be evaluated at treatment Weeks 1, 2, 4, 8, 12, and 16. HBeAg, HBsAg, andALT should be evaluated at the end of therapy, as well as 3- and 6-months posttherapy,since patients may become virologic responders during the 6-month periodfollowing the end of treatment. In clinical studies in adults, 39% (15/38) of respondingpatients lost HBeAg 1 to 6 months following the end of INTRON A therapy. Ofresponding patients who lost HBsAg, 58% (7/12) did so 1 to 6 months post-treatment.A transient increase in ALT greater than or equal to 2 times baseline value (flare)can occur during INTRON A therapy for chronic hepatitis B. In clinical trials in adultsand pediatrics, this flare generally occurred 8 to 12 weeks after initiation of therapy andwas more frequent in responders (adults 63%, 24/38; pediatrics 59%, 10/17) than innonresponders (adults 27%, 13/48; pediatrics 35%, 19/55). However, in adults andpediatrics, elevations in bilirubin greater than or equal to 3 mg/dL (greater than or equalto 2 times ULN) occurred infrequently (adults 2%, 2/86; pediatrics 3%, 2/72) duringtherapy. When ALT flare occurs, in general, INTRON A therapy should be continued unless signs and symptoms of liver failure are observed. During ALT flare, clinicalsymptomatology and liver function tests including ALT, prothrombin time, alkalinephosphatase, albumin, and bilirubin, should be monitored at approximately 2-weekintervals (see WARNINGS).
DrugBank Targets:13 1. Interferon alpha/beta receptor 2;2. Interferon alpha/beta receptor 1
Mechanism of Action:15 
Target: intracellular oncogene expression, natural killer and cytotoxic T-cells, microphage, cytokine production
Action: stimulation, induction (unspecified effects on oncogene expression)
FDA: -
3
Taxol15 41 PACLITAXEL Bristol-Myers Squibb August 1997
FDA Label: Taxol
Disease/s that Drug Treats:Kaposi's Sarcoma
Indications and Usage:15 Paclitaxel Injection, USP is indicated as subsequent therapy for the treatment of advanced carcinoma ofthe ovary. As first-line therapy, Paclitaxel Injection, USP is indicated in combination with cisplatin.Paclitaxel Injection, USP is indicated for the adjuvant treatment of node-positive breast canceradministered sequentially to standard doxorubicin-containing combination chemotherapy.. In the clinicaltrial, there was an overall favorable effect on disease-free and overall survival in the total population ofpatients with receptor-positive and receptor-negative tumors, but the benefit has been specifically demonstrated by available data (median follow-up 30 months) only in the patients with estrogen andprogesterone receptor-negative tumors (see CLINICAL STUDIES, Breast Carcinoma).Paclitaxel Injection, USP is indicated for the treatment of breast cancer after failure of combinationchemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapyshould have included an anthracycline unless clinically contraindicated.Paclitaxel Injection, USP, in combination with cisplatin, is indicated for the first-line treatment of nonsmallcell lung cancer in patients who are not candidates for potentially curative surgery and/or radiationtherapy.Paclitaxel Injection, USP is indicated for the second-line treatment of AIDS-related Kaposi’s sarcoma.
DrugBank Targets:13 1. Apoptosis regulator Bcl-2;2. Tubulin beta-1 chain;3. Nuclear receptor subfamily 1 group I member 2;4. Microtubule-associated protein 4;5. Microtubule-associated protein 2;6. Microtubule-associated protein tau
Mechanism of Action:15 
Target: microtubules
Action: promoter of assembly & preventor of depolymerization
FDA: Paclitaxel is a novel antimicrotubule agent that promotes the assembly of microtubules from tubulindimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibitionof the normal dynamic reorganization of the microtubule network that is essential for vital interphase andmitotic cellular functions. In addition, paclitaxel induces abnormal arrays or “bundles” of microtubulesthroughout the cell cycle and multiple asters of microtubules during mitosis.Following intravenous administration of paclitaxel, paclitaxel plasma concentrations declined in abiphasic manner. The initial rapid decline represents distribution to the peripheral compartment andelimination of the drug. The later phase is due, in part, to a relatively slow efflux of paclitaxel from theperipheral compartment.Pharmacokinetic parameters of paclitaxel following 3- and 24-hour infusions of paclitaxel at dose levelsof 135 and 175 mg/m2 were determined in a Phase 3 randomized study in ovarian cancer patients and aresummarized in the following table:

Drugs for Kaposi Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 183)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Ritonavirapproved, investigationalPhase 4, Phase 2, Phase 3, Phase 1850155213-67-5392622
Synonyms:
1,3-thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[[(2S)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate
155213-67-5
1hxw
1sh9
5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S)-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate
5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate
538, ABT
A-84538
ABBOTT-84538
ABT 538
ABT 84538
ABT-538
ABT538
AC-733
AC1L94GB
AKOS000280930
Abbott 84538
BIDD:GT0387
BIDD:PXR0023
Bio-0093
C07240
C37H48N6O5S2
CHEBI:45409
CHEMBL163
CID392622
CPD000466395
D00427
D019438
 
DB00503
DRG-0244
FT-0082824
HMS2051B08
HSDB 7160
LS-148860
MLS000759541
MLS001424063
MolPort-000-883-877
N-[(2S,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl]-N~2~-(methyl{[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl}carbamoyl)-L-valinamide
NCGC00159462-02
NSC693184
Norvir
Norvir (TM)
Norvir (TN)
Norvir Sec
RIT
RTV
Ritonavir
Ritonavir (JAN/USAN/INN)
Ritonavir [USAN]
Ritonavir is an inhibitor of HIV protease used to treat HIV infection and AIDS.
Ritonavirum
S1185_Selleck
SAM001246783
SMR000466395
STK634209
ZINC03944422
ritonavir
2
LopinavirapprovedPhase 4, Phase 2, Phase 3342192725-17-092727
Synonyms:
(1S-(1R*(R*),3R*,4R*))-N-(4-(((2,6-Dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2H)-pyrimidineacetamide
(2S)-N-[(2S,4S,5S)-5-[[2-(2,6-dimethylphenoxy)acetyl]amino]-4-hydroxy-1,6-diphenylhexan-2-yl]-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide
(alphaS)-Tetrahydro-N-((alphaS)-alpha-((2S,3S)-2-hydroxy-4-phenyl-3-(2-(2,6-xylyloxy)acetamido)butyl)phenethyl)-alpha-isopropyl-2-oxo-1(2H)-pyrimidineacetamide
1(2H)-Pyrimidineacetamide, N-[(1S,3S,4S)-4-[[(2,6-dimethylphenoxy)acetyl]amino]-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl]tetrahydro-alpha-(1-methylethyl)-2-oxo-, (alphaS)- (9CI)
192725-17-0
1mui
2o4s
2q5k
2rkf
2rkg
A 157378
A 157378.0
A-157378-0
A-157378.0
AB1
ABT 157378
ABT 378
ABT-378
ABT-378, LOPINAVIR
AC1L3OPJ
AIDS032937
Aluviran
C12871
C37H48N4O5
 
CHEBI:40456
CHEMBL729
CID92727
D01425
DB01601
Kaletra
Koletra
LPV
LS-173766
Lopinavir
Lopinavir (JAN/USAN/INN)
Lopinavir [USAN:INN:BAN]
MolPort-003-848-410
N-(4-(((2,6-dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2H)-pydrimidineacetamide
N-{1-BENZYL-4-[2-(2,6-DIMETHYL-PHENOXY)-ACETYLAMINO]-3-HYDROXY-5-PHENYL-PENTYL}-3-METHYL-2-(2-OXO-TETRAHYDRO-PYRIMIDIN-1-YL)-BUTYRAMIDE
NCGC00164576-01
NCGC00164576-02
RS-346
S1380_Selleck
SID124893167
SID144205757
SID50111692
UNII-2494G1JF75
a-157378-0
a-157378.0
3
Tenofovirapproved, investigationalPhase 4, Phase 3666147127-20-6464205
Synonyms:
(R)-9-(2-Phosphonomethoxypropyl)adenine
(R)-9-(2-Phosphonylmethoxypropyl)adenine
(R)-PMPA
147127-20-6
206184-49-8
AC-760
AC1LA9BO
Anh. tenofovir
Anhydrous tenofovir
Apropovir
CHEBI:45809
CHEMBL483
CID464205
D,L-Tenofovir
DB00300
GNA & Tenofovir
GS 1275
GS 1278
GS1278
HHA & Tenofovir
 
KS-5021
MolPort-003-850-411
NCGC00167535-01
PMPA
PMPA-(R)
Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]- & Galanthus nivalis agglutinin (GNA)
Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]- & Hippeastrum hybrid agglutinin( HHA)
Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]- (9CI)
Phosphonic acid, [[2-(6-amino-9H-purin-9
S1401_Selleck
TDF
TFV
Tenefovir
Tenofovir
Tenofovir (anh.)
Tenofovir Disoproxil Fumarate
Tenofovir disoproxil
Tenofovir disoproxil fumarate
UNII-99YXE507IL
Viread
Viread, Tenofovir
[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethylphosphonic acid
4
Ganciclovirapproved, investigationalPhase 4, Phase 214082410-32-03454
Synonyms:
106931-35-5
107910-75-8 (mono-hydrochloride salt)
2'-NDG
2'-Nor-2'-deoxyguanosine
2-(6-Amino-purin-9-ylmethoxy)-propane-1,3-diol
2-Amino-1,9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)-6-H-purin-6-one
2-Amino-9-(2-hydroxy-1-hydroxymethyl-ethoxymethyl)-1,9-dihydro-purin-6-one
2-amino-9-((1,3-Dihydroxypropan-2-yloxy)methyl)-1H-purin-6(9H)-one
2-amino-9-((1,3-Dihydroxypropan-2-yloxy)methyl)-3H-purin-6(9H)-one
2-amino-9-((1,3-Dihydroxypropan-2-yloxy)methyl)-9H-purin-6-ol
2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-1H-purin-6(9H)-one
2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-3H-purin-6(9H)-one
2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-9H-purin-6-ol
2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)-3H-purin-6-one
2-amino-9-(2-Hydroxy-1-hydroxymethylethoxymethyl)-6,9-dihydro-1H-6-purinone
2-amino-9-(2-hydroxy-1-hydroxymethylethoxymethyl)-6,9-dihydro-1H-6-purinone
2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-1,9-dihydro-6H-purin-6-one
2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-6,9-dihydro-3H-purin-6-one
82410-32-0
86357-12-2
9-((1,3-Dihydroxy-2-propoxy)methyl)guanine
9-((2-Hydroxy-1-(hydroxymethyl)ethoxy)methyl)guanine
9-(1,3-DIHYDROXY-PROPOXYMETHANE)GUANINE
9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine
9-[(1,3-dihydroxy-2-propoxy)methyl]guanine
96551-29-0
AC-12604
AC1L1FZ2
AC1Q52OB
AKOS004119898
BB_NC-1042
BIDD:GT0783
BIOLF-62
BPBio1_000877
BSPBio_000797
BW 759
BW 759U
BW-759U
BW-795
BW-B 759U
Biolf 62
CAS-82410-32-0
CCRIS 9212
CHEBI:465284
CHEMBL182
CID3454
CPD000058324
Citovirax
Cymevan
Cymeven
Cymevene
Cytovene
Cytovene (TN)
Cytovene IV
Cytovene-IV
D00333
DB01004
DRG-0018
EU-0100539
 
G 2536
G2536_SIGMA
GA2
GANCICLOVIR SODIUM
GCV & 1110U81
GCV & MSL
Ganciclovir
Ganciclovir & C34-dgA immunotoxin
Ganciclovir & D5-dgA immunotoxin
Ganciclovir (JAN/USP/INN)
Ganciclovir Sodium
Ganciclovir [USAN:INN:BAN:JAN]
Ganciclovirum
Ganciclovirum [Latin]
Gancyclovir
Guanine, 9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)- and MSL, neutralizing monoclonal antibody
HHEMG
HMS1570H19
HMS2090K08
HSDB 6512
Hydroxyacyclovir
I07-0010
IN1478
LS-73939
Lopac-G-2536
Lopac0_000539
MB3795
MLS000028481
MLS001077349
MolPort-000-758-398
MolPort-002-507-301
NCGC00015471-01
NCGC00015471-02
NCGC00015471-03
NCGC00015471-06
NCGC00093928-01
NCGC00093928-02
NCGC00168567-01
PDSP1_000816
PDSP2_000803
Prestwick0_000839
Prestwick1_000839
Prestwick2_000839
Prestwick3_000839
Prestwick_1068
RS-21592
SAM002548936
SMP2_000038
SMR000058324
SPBio_002718
ST-605
STK801910
UNII-P9G3CKZ4P5
Virgan
Vitrasert
Vitrasert (TN)
ZINC00001505
Zirgan
ganciclovir
nchembio.87-comp3
5
BleomycinapprovedPhase 4, Phase 3, Phase 2, Phase 114411056-06-75360373
Synonyms:
(betaR)-N(alpha)-{[6-amino-2-((1S)-3-amino-1-{[(2S)-2,3-diamino-3-oxopropyl]amino}-3-oxopropyl)-5-methylpyrimidin-4-yl]carbonyl}-beta-{2-O-[3-O-(aminocarbonyl)-alpha-D-mannopyranosyl]-alpha-L-gulopyranosyloxy}-N-[(1R,2S,3S)-5-({(1S,2R)-1-[({2-[4-({[3-(dimethylsulfonio)propyl]amino}carbonyl)-2,4'-bi-1,3-thiazol-2'-yl]ethyl}amino)carbonyl]-2-hydroxypropyl}amino)-3-hydroxy-4-methyl-5-oxopentan-2-yl]-L-histidinamide
11056-06-7
11116-31-7
1400-95-9
3-[[2-[2-[2-[[(2S,3R)-2-[[(2S,3S,4R)-4-[[(2S)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2R,3S,4S,5S,6S)-3-[(2R,3S,4S,5R,6R)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxy-2-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]ethyl]-1,3-thiazol-4-yl]-1,3-thiazole-4-carbonyl]amino]propyl-dimethylsulfanium
3-[[2-[2-[2-[[(2S,3R)-2-[[(2S,3S,4R)-4-[[(2S,3R)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2R,3S,4S,5S,6S)-3-[(2R,3S,4S,5R,6R)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxy-2-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]ethyl]-1,3-thiazol-4-yl]-1,3-thiazole-4-carbonyl]amino]propyl-dimethylsulfanium
3-[[2-[2-[2-[[(2S,3R)-2-[[(2S,3S,4R)-4-[[(2S,3R)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[3-[4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxy-2-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]ethyl]-1,3-thiazol-4-yl]-1,3-thiazole-4-carbonyl]amino]propyl-dimethylsulfanium
37208-04-1
37293-16-6
37353-43-8
9041-93-4
9041-93-4 (sulfate (salt))
AC1L9UFF
AC1NSEJD
AC1NUTOQ
BLM
Blenoxane
Bleo
Bleocin
Bleogin
Bleomicin
Bleomicina
Bleomicina [INN-Spanish]
Bleomycin
Bleomycin A(2)
Bleomycin A2
Bleomycin A2 & Bleomycin B2.
Bleomycin B(2)
Bleomycin B2
Bleomycin sulfate
Bleomycin sulphate
 
Bleomycine
Bleomycine [INN-French]
Bleomycins
Bleomycinum
Bleomycinum [INN-Latin]
C06854
C55H85N17O21S3
C55H86N17O21S3
CCRIS 2754
CHEBI:3139
CHEMBL403664
CID456190
CID5360373
CID5460769
DB00290
EINECS 234-356-5
HSDB 3208
LMPK14000006
LS-44860
LS-524
N(1)-[3-(dimethylsulfonio)propyl]bleomycinamide
N1-(3-(Dimethylsulfonio)propyl)bleomycinamide
NDC 0015-3010
NSC 125066
Pingyangmyvin A2
STOCK1N-74760
UNII-13M89UEA7W
UNII-40S1VHN69B
Zhengguangmycin A2
Zhengguangmycin A2 [Chinese]
bleomycin
bleomycin a2
6
Valganciclovirapproved, investigationalPhase 4, Phase 276175865-60-864147
Synonyms:
175865-60-8
5-Amino-3-[1-(hydroxymethyl)-2-(L-valyloxy)ethoxymethyl]-6,7-dihydro-3H-imidazo[4,5-d]pyrimidin-7-one
AC1L20JF
AC1Q63EV
C14H22N6O5
CID64147
Cymeval
D02495
DB01610
I06-1704
L-Valine, 2-((2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy)-3-hydroxypropyl ester
 
L-Valine, ester with ganciclovir
L-valine, ester with ganciclovir
LS-173677
NCGC00168779-01
RO1079070/194
RS 79070
UNII-GCU97FKN3R
Valcyte
Valganciclovir
Valganciclovir (INN)
Valganciclovir (Oral)
Valganciclovir [INN:BAN]
[2-[(2-amino-6-oxo-3H-purin-9-yl)methoxy]-3-hydroxypropyl] (2S)-2-amino-3-methylbutanoate
7
Efavirenzapproved, investigationalPhase 4, Phase 3398154598-52-464139
Synonyms:
(-)-6-CHLORO-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one
(-)-Efavirenz
(4S)-6-Chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one
(4S)-6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
(4S)-6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-1H-3,1-benzoxazin-2-one
(4S)-6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-1,4-dihydro-2H-3,1-benzoxazin-2-one
(S)-6-Chloro-4-(2-cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-ben
(S)-6-Chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one
(S)-6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
(S)-6-chloro-4-(Cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one
(S)-6-chloro-4-Cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[D][1,3]oxazin-2-one
154598-52-4
1ikv
1ikw
2H-3,1-Benzoxazin-2-one, 6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-, (4S)- (9
6-chloro-4-(2-Cyclopropyl-1-ethynyl)-4-trifluoromethyl-(4S)-1,4-dihydro-2H-benzo[D][1,3]oxazin-2-one
6-chloro-4-(2-cyclopropyl-1-ethynyl)-4-trifluoromethyl-(4S)-1,4-dihydro-2H-benzo[d][1,3]oxazin-2-one
AC-19049
AC1L20IX
BIDD:GT0383
C08088
C14H9ClF3NO2
CHEBI:119486
CHEMBL223228
CID64139
CPD000466351
D00896
DB00625
DB07709
DMP 266
DMP-266
EFV
 
EFZ
Efavirenz
Efavirenz (JAN/INN)
Efavirenzum
Eravirenz
HMS2051J08
HMS2090N16
HSDB 7163
L 743726
L-741211
L-743,726
L-743725
L-743726
LS-173464
MLS000759465
MLS001424087
Met-SDF-1.beta. & Efavirenz
Met-Stromal Cell-derived Factor-1.beta. (Human) & Efavirenz
MolPort-003-983-924
NSC742403
SAM001246667
SBB066062
SMR000466351
Stocrin
Strocin (TM)
Sustiva
Sustiva (TM)
Sustiva (TN)
UNII-JE6H2O27P8
ZINC02020233
efavirenz
efavirenz, (S)-isomer
zoxazin-2-one
Éfavirenz
8
Emtricitabineapproved, investigationalPhase 4, Phase 3394143491-57-060877
Synonyms:
(-)-(2R,5S)-5-Fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
(-)-(2R,5S)-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
(-)-.beta.-L-FTC
(-)-2',3'-Dideoxy-5-fluoro-3'-thiacytidine
(-)-2'-Deoxy-5-fluoro-3'-thiacytidine
(-)-FTC
(-)-beta-2',3'-Dideoxy-5-fluoro-3'-thiacytidine
(-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine
(-)-cis-4-amino-5-Fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one
(-)-cis-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one
(2R-cis)-4-Amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone
(2R-cis)-4-amino-5-Fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone
.beta.-L-(-)-(2R,5S)-5-Fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
1-(2-(Hydroxymethyl)oxathiolan-5-yl)-5-fluorocytosine
143491-54-7
143491-57-0
145213-48-5
2',3',5-FTC
2',3'-Dideoxy-5-fluoro-3'-thiacytidine
2'-Deoxy-5-fluoro-3'-oxa-4'-thiocytidine
2'-Deoxy-5-fluoro-3'-thiacytidine
2-FTC
3'-Thia-2'.3'-dideoxy-5-fluorocytidine
4-Amino-5-fluoro-1-((2R,5S)-2-hydroxymethyl-[1,3]oxathiolan-5-yl)-1H-pyrimidin-2-one
4-Amino-5-fluoro-1-[(2R,5S)-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone
4-amino-5-Fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1H)-one
4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one
4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one
5-Fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine
5-Fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine
5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)[1,3]oxathiolan-5-yl]cytosine
524W91
AC1L1U3I
AC1Q4KUB
BW 1592
 
BW 524W91
BW-524W91
BW524W91
C122114
C12599
C8H10FN3O3S
CHEBI:31536
CHEMBL885
CID60877
Coviracil
Coviracil(TM)
D01199
DB00879
DRG-0208
Emtricitabin
Emtricitabina
Emtricitabine
Emtricitabine (JAN/USAN/INN)
Emtricitabinum
Emtriva
Emtriva (TN)
Emtriva(TM)
FT-0080009
HMS2089I05
HSDB 7337
LS-135838
LS-173184
NCGC00164564-01
RCV
Racivir
SBB066061
TL8000958
UNII-G70B4ETF4S
ZINC03629271
beta-L-2',3'-dideoxy-5-fluoro-3'-thiacytidine
dOTFC
emtricitabine
9
Stavudineapproved, investigationalPhase 41723056-17-518283
Synonyms:
1-(2,3-Dideoxy-beta-D-glycero-2-pentenofuranosyl)thymine
1-(2,3-Dideoxy-beta-D-glycero-pent-2-enofuranosyl)thymine
1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4(1H,3H)-dione
1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4-dione
1-[5-(hydroxymethyl)-2,5-dihydro-2-furanyl]-5-methyl-2,4(1H,3H)-pyrimidinedione & Colony-stimulating factor 2
132425-31-1
2',3' Didehydro 3' deoxythymidine
2',3'-Anhydrothymidine
2',3'-DIDEHYDRO-3'-DEOXYTHYMIDINE (DDI)
2',3'-Didehydro-2',3'-dideoxythmidine
2',3'-Didehydro-3'-deoxythimidine
2',3'-Didehydro-3'-deoxythymidine
3'- Azido-3'-deoxythymidine & Granulocyte-macrophage colony-stimulating factor
3'-Deoxy-2',3'-didehydrothymidine
3'-Deoxy-2'-thymidinene
3056-17-5
AC-5263
AC1L2BQ9
AC1Q6BSH
BB_NC-1008
BIDD:GT0082
BMY 27857
BMY-27857
BMY27857
BRN 0618327
Bristol-Myers Brand of Stavudine
Bristol-Myers Squibb Brand of Stavudine
C07312
CHEBI:207119
CHEMBL991
CID18283
CPD000058350
CPD000673569
D 1413
D 4T
D 4T (nucleoside)
D00445
D018119
D1413_SIGMA
D3580
D4T & GM-CSF
D4TMBY-27857-3
DB00649
Dideoxydidehydrothymidine
EU-0100336
Estavudina
Estavudina [INN-Spanish]
FT-0082665
 
HMS2051O20
HSDB 7338
LS-1160
Lopac0_000336
MLS000028546
MLS000759504
MLS001055348
MLS001077292
MolPort-002-507-283
NCGC00023212-03
NCGC00023212-04
NCGC00023212-05
NCGC00023212-07
NCGC00023212-08
NCGC00023212-09
NCGC00023212-10
NSC 163661
NSC163661
SAM001246729
SAM002589948
SMR000058350
SMR000673569
STK801888
STV
Sanilvudine
Sanilvudine (JAN)
Stavudin
Stavudine
Stavudine (USAN/INN)
Stavudine [USAN:BAN:INN]
Stavudine [USAN:INN:BAN]
Stavudine [Usan:Ban:Inn]
Stavudine, Monosodium Salt
Stavudinum
Stavudinum [INN-Latin]
Thymine, 1-(2,3-dideoxy-beta-D-glycero-pent-2-enofuranosyl)- (7CI,8CI)
UNII-BO9LE4QFZF
ZINC00137884
Zent
Zerit
Zerit (TN)
Zerit Xr
Zerit(TM)
Zerut XR
d4T
ddeThd
ddeTyd
sanilvudine
stavudine
10
Vincristineapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 18632068-78-2, 57-22-75978
Synonyms:
22-Oxovincaleukoblastin
22-Oxovincaleukoblastine
28379-27-3
57-22-7
AC1L1LJC
C07204
C46H56N4O10
CCRIS 5763
CHEBI:28445
CID5978
D08679
DB00541
EINECS 200-318-1
HMS2090E19
HSDB 3199
Indole alkaloid
LCR
LS-228
Leurocristine
Lilly 37231 (1:1 sulfate salt)
Liposomal Vincristine
Marqibo
NCGC00163700-01
NCI-C04864
NCI60_026703
NSC-67574
Onco TCS
 
Oncovin
Oncovin (1:1 sulfate salt)
Oncovine
Tecnocris
Tecnocris (TN)
UNII-5J49Q6B70F
VCR
VIN
Vincaleukoblastine, 22-oxo- 22-Oxovincaleukoblastine
Vincasar
Vincasar (1:1 sulfate salt)
Vincasar PFS
Vincrex
Vincrex (1:1 sulfate salt)
Vincristin
Vincristina
Vincristina [DCIT]
Vincristine (INN)
Vincristine Sulfate
Vincristine Sulfate PFS
Vincristine [INN:BAN]
Vincristinum
Vincristinum [INN-Latin]
Vincrstine
Vincrystine
Vinkristin
Z-D-Val-Lys(Z)-OH
vincristine
11
NevirapineapprovedPhase 4, Phase 3222129618-40-24463
Synonyms:
11-CYCLOPROPYL-5,11-DIHYDRO-4-METHYL-6H-DIPYRIDO[3,2-B:2',3'-E][1,4]DIAZEPIN-6-ONE
11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one
11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one & PRO 140 (Anti-CCR5 monoclonal antibody)
11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one
11-Cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one
129618-40-2
1vrt
2hny
AC-643
AC1L1I81
BI RG 587
BI-RG-587
BI-RG-587 & CD4-IgG
BIDD:GT0326
BIRG 0587
BIRG 587
BIRG-0587
BIRG-587
BIRG587
Bio-0789
C07263
C15H14N4O
CHEBI:44659
CHEMBL57
CID4463
CPD000048458
Cahill May Roberts Brand of Nevirapine
D00435
D019829
DB00238
DB08311
 
HMS2051J09
HSDB 7164
I02-0310
LS-2289
MLS000084585
MLS000759409
MLS001055309
MLS001201730
MolPort-002-507-817
N11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e]-[1,4]diazepin-6-one & CD4-immunoadhesin
NCGC00065890-02
NEV
NON-NUCLEOSIDE RT INHIBITOR NEVIRAPINE
NSC 641530
NSC641530
NVP
Nevirapine
Nevirapine & CD4-IgG
Nevirapine & PRO 140
Nevirapine (JAN/USP/INN)
Nevirapine [USAN:INN]
Promeco Brand of Nevirapine
S1742_Selleck
SAM001246551
SMR000048458
STK580320
UNII-99DK7FVK1H
Viramune
Viramune (TN)
Viramune(TM)
Viramune, BI-RG 587, Nevirapine
ZINC00004778
nevirapine
12
Lamivudineapproved, investigationalPhase 4, Phase 2, Phase 3594134678-17-460825
Synonyms:
(+/-) (Cis)-1-[2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
(+/-)-3TC
(+/-)-BCH-189
(+/-)-SddC
(-)-(2'R,5'S)-1-[2'-Hydroxymethyl-5'-(1,3-oxathiolanyl)]cytosine
(-)-1-((2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine
(-)-1-[(2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
(-)-2'-Deoxy-3'-thiacytidine
(-)-BCH 189
(-)-BCH-189
(-)-SddC
(-)-beta-L-2',3'-Dideoxy-3'-thiacytidine
(-)NGPB-21
(2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one
.beta.-L-(-)-2',3'-dideoxy-3'-thiacytidine & Sho-Saiko-To
134678-17-4
2',3' Dideoxy 3' thiacytidine
2',3'-Dideoxy-3'-thiacytidine
2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (+/-) (Cis)
2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)(2R,5S)
2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)(2R,5S) & Galanthus Nivalis Agglutinin (GNA)
2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)(2R,5S) & Hippeastrum hybrid agglutinin( HHA)
3'-Thia-2',3'-dideoxycytidine
3-TC
3TC
3TC & GNA
3TC & SST
3TC (AIDS INITIATIVE) (AIDS INITIATIVE)
3TC and NV-01
3TC, Zeffix, Heptovir, Epivir, Epivir-HBV, Lamivudine
4-Amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone
4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one
4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one
480434-79-5
AC-1416
AC1L1TZZ
AC1Q6C34
BCH 189
BCH-189
BCH-790
BCH189
BIDD:GT0033
Bio-0652
C07065
C8H11N3O3S
CCRIS 9274
CHEBI:133986
CHEMBL141
CID60825
CPD000466319
D00353
D019259
DB00709
 
DRG-0126
DTHC
Epivir
Epivir (TN)
Epivir HBV
Epivir(TM)
Epivir-HBV
Epzicom
FT-0082667
GG-714
GR 109714 X
GR 109714X
GR-109714X
GR109714X
HHA & 3TC
HHA & Lamivudine
HMS2051D21
HSDB 7155
Hepitec
Heptivir
Heptodin
Heptovir
L0217
LMV
LS-2107
Lamivir
Lamivudin
Lamivudina
Lamivudine
Lamivudine & GNA
Lamivudine (JAN/USP/INN)
Lamivudine [USAN:BAN:INN]
Lamivudine [USAN:INN:BAN]
Lamivudine [Usan:Ban:Inn]
Lamivudine, (2S-cis)-Isomer
Lamivudinum
MLS000759424
MLS001424097
MolPort-002-507-347
NCGC00159341-03
NCGC00159341-04
NSC620753
S1706_Selleck
SAM001246582
SAM002589994
SMR000466319
STK801940
UNII-2T8Q726O95
ZINC00012346
Zeffix
Zefix
beta-L-2',3'-Dideoxy-3'-thiacytidine
beta-L-3'-Thia-2',3'-dideoxycytidine
lamivudine
13
Doxorubicinapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1158223214-92-831703
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(8S-cis)-10-((3-amino-2,3,6-Trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
111266-55-8
14-Hydroxydaunomycin
14-Hydroxydaunorubicine
14-hydroxydaunomycin
14-hydroxydaunorubicine
23214-92-8
23257-17-2
24385-08-8
25311-50-6
25316-40-9
25316-40-9 (hydrochloride)
29042-30-6
AC1L1M5T
AC1Q29OJ
ADM
ADR
Adriablastin
Adriacin (hydrochloride salt)
Adriamycin
Adriamycin PFS
Adriamycin PFS (hydrochloride salt)
Adriamycin RDF
Adriamycin RDF (hydrochloride salt)
Adriamycin Semiquinone
Adriamycin semiquinone
Adriblas tina
Adriblastin
Adriblastina
Adriblastina (TN)
Adriblastina (hydrochloride salt)
Aerosolized Doxorubicin
BPBio1_000502
BRD-K92093830-003-04-3
BSPBio_000456
BSPBio_001031
C01661
C27H29NO11
CCRIS 739
CHEBI:28748
CHEMBL179
CID31703
Caelyx
Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74
Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120
D03899
DB00997
DM2
DOX-SL
Doxil
Doxo
Doxorubicin
Doxorubicin (USAN/INN)
Doxorubicin HCl
 
Doxorubicin Hydrochloride
Doxorubicin [USAN:INN:BAN]
Doxorubicin citrate
Doxorubicin hydrochloride (hydrochloride salt)
Doxorubicin-P4/D10
Doxorubicin-P4/D10 conjugate
Doxorubicin-hLL1
Doxorubicin-hLL1 conjugate
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicine
Doxorubicine [INN-French]
Doxorubicinum
Doxorubicinum [INN-Latin]
EINECS 245-495-6
FI 106
Farmablastina (hydrochloride salt)
HMS2089H06
HSDB 3070
Hydroxydaunomycin hydrochlor ide (hydrochloride salt)
Hydroxydaunomycin hydrochloride (hydrochloride salt)
Hydroxydaunorubicin
Hydroxydaunorubicin hydrochloride (hydrochloride salt)
JT9100000
LMPK13050001
LS-1029
LS-165655
MLS000759533
Myocet
NCI-C01514
NChemBio.2007.10-comp13
NDC 38242-874
NIOSH/JT9100000
NSC 123127
Prestwick0_000438
Prestwick1_000438
Prestwick2_000438
Prestwick3_000438
Probes1_000151
Probes2_000129
RDF Rubex
Resmycin
Rubex
Rubex (hydrochloride salt)
SMP1_000106
SPBio_002395
TLC D-99
ThermoDox
Triferric doxorubicin
UNII-80168379AG
adiblastine (hydrochloride salt)
adr iablatina (hydrochloride salt)
adriablastine (hydrochloride salt)
adriablatina (hydrochloride salt)
adriblatina (hydrochloride salt)
doxorubicin
nchembio809-comp5
14
DoxilApproved June 1999Phase 4, Phase 3, Phase 2, Phase 1158231703
Synonyms:
Dox-SL
Doxil
 
Evacet
LipoDox
Pegylated Liposomal Doxorubicin Hydrochloride
liposomal doxorubicin
15Protease InhibitorsPhase 4, Phase 2, Phase 3, Phase 1, Phase 04558
16Reverse Transcriptase InhibitorsPhase 4, Phase 2, Phase 3, Phase 11656
17Anti-Retroviral AgentsPhase 4, Phase 2, Phase 3, Phase 1, Phase 02794
18Ganciclovir triphosphatePhase 4, Phase 2140
19Nucleic Acid Synthesis InhibitorsPhase 4, Phase 2, Phase 3, Phase 13836
20HIV Protease InhibitorsPhase 4, Phase 2, Phase 3, Phase 1, Phase 04558
21Cytochrome P-450 CYP2C9 InhibitorsPhase 4, Phase 3497
22Antiviral AgentsPhase 4, Phase 2, Phase 3, Phase 1, Phase 08071
23Cytochrome P-450 Enzyme InhibitorsPhase 4, Phase 2, Phase 33036
24Cytochrome P-450 CYP3A InhibitorsPhase 4, Phase 2, Phase 31421
25Anti-Infective AgentsPhase 4, Phase 2, Phase 3, Phase 1, Phase 017220
26Emtricitabine, Tenofovir Disoproxil Fumarate Drug CombinationPhase 4, Phase 3130
27
Abacavirapproved, investigationalPhase 2, Phase 3203136470-78-565140, 441300
Synonyms:
(+/-)-4-[2-Amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol
(+/-)-Abacavir
(1S,4R)-4-[2-Amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol
136470-78-5
1592U89
168146-84-7
ABC
AC1L9AXG
Abacavir
Abacavir (INN)
Abacavir Sulfate
Abacavir [INN]
Bio-0001
C07624
 
CHEBI:421707
CHEMBL1380
CID441300
D07057
DB01048
Epzicom
NCGC00164560-01
NCGC00164560-02
NSC742406
Trizivir
ZINC02015928
Ziagen
Ziagen (TM)(*Succinate salt*)
[(1S,4R)-4-[2-amino-6-(cyclopropylamino)purin-9-yl]cyclopent-2-en-1-yl]methanol
abacavir
{(1S-cis)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]cyclopent-2-en-1-yl}methanol
28
DaunorubicinapprovedPhase 3, Phase 125220830-81-330323
Synonyms:
(+)-Daunomycin
(1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside
(7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
(7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
(8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione
(8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro--6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione
11006-54-5
11048-29-6
1407-15-4
149541-57-1
20830-81-3
23942-76-9
27576-81-4
28020-80-6
AB00514669
AC1L1JCP
AC1Q29OI
AI3-52942
Acetyladriamycin
Anthracyline
Antibiotics From Streptomyces Coeruleorubidus
Antibiotics from Streptomyces coeruleorubidus
BPBio1_000389
BRD-K43389675-003-02-7
BRN 1445583
BSPBio_000353
C01907
CCRIS 914
CHEBI:41977
CHEMBL178
CID30323
Cerubidin
Cerubidine
D07776
DAUNORUBICIN HCL
DB00694
DM1
Daunamycin
Daunarubicinum
Dauno-Rubidomycine
DaunoXome
DaunoXome (TN)
Daunoblastin
Daunoblastine
Daunomycin
 
Daunomycin Hydrochloride
Daunomycin, Hydrochloride
Daunorrubicina
Daunorubicin
Daunorubicin (INN)
Daunorubicin (liposomal)
Daunorubicin Hcl
Daunorubicin Hydrochloride
Daunorubicin [INN:BAN]
Daunorubicin, Hydrochloride
Daunorubicina
Daunorubicine
Daunorubicinum
Daunorubicinum [INN-Latin]
Daunoxome
EINECS 244-069-7
FI 6339
FI6339
HMS2089H04
HMS2091K06
HSDB 5095
LMPK13050002
LS-187381
LS-997
Leukaemomycin C
MolPort-002-533-961
NCGC00024246-05
NCGC00024246-06
NCGC00025173-01
NCI-C04693
NChemBio.2007.10-comp14
NSC 83142
NSC-82151
Ondena
Prestwick3_000487
RCRA waste no. U059
RP 13057
Rcra Waste No. U059
Rp 13057 Hydrochloride
Rubidomycin
Rubidomycin Hydrochloride
Rubomycin
Rubomycin C
Tocris-1467
UNII-ZS7284E0ZP
VS-103
daunorubicin
nchembio723-comp2
29
EtoposideapprovedPhase 3, Phase 2, Phase 1116933419-42-036462
Synonyms:
(-)-Etoposide
121471-01-0
136598-18-0
201594-04-9
33419-42-0
35317-32-9
4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin ethylidene-.beta.-D-glucoside
4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin
4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside
4-Demethylepipodophyllotoxin-.beta.-D-ethylideneglucoside
51854-34-3
76576-58-4
9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
AB00438905
AC1L1FN8
AC1L1VT3
AC1L6246
AC1NR4OG
AC1O4WGG
AC1O7M1N
AC1Q47JJ
Ambap33419-42-0
BPBio1_000673
BRD-K37798499-001-02-5
BSPBio_000611
Bio1_000489
Bio1_000978
Bio1_001467
C01576
CCRIS 2392
CHEBI:4911
CHEBI:588795
CHEMBL44657
CID11758093
CID284997
CID3310
CID36462
CID5284558
CID6419930
CID6610299
CPD000112002
D00125
DB00773
DEMETHY-EPIPODOPHYLLOTOXIN,ETHYLIDENE GLUCOSIDE,
Demethyl Epipodophyllotoxin Ethylidine Glucoside
Demethyl-epiodophyllotoxin ethylidene glucoside
Demethylepipodophyllotoxin-beta-D-ethylideneglucoside
E0675
E1383_SIGMA
EINECS 251-509-1
EPE
EPEG
ETOP
Epipodophyllotoxin
Epipodophyllotoxin VP-16213
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-.beta.-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside (8CI)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-.beta.-D-glucopyranoside)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
Eposide
Eposin
Eposin, Vepesid, VP-16, Toposar, Etoposide
 
Etopol
Etopophos
Etopophos (phosphate salt)
Etoposid
Etoposide
Etoposide (JP15/USP/INN)
Etoposide (VP16)
Etoposide Phosphate
Etoposide [USAN:INN:BAN:JAN]
Etoposido
Etoposido [INN-Spanish]
Etoposidum
Etoposidum [INN-Latin]
Etosid
HMS1569O13
HMS2052N05
HMS2089F14
HSDB 6517
I06-0248
KBioSS_002410
LS-1214
Lastet
MLS000049957
MLS001074951
MLS001424283
MLS002153463
MLS002207239
MLS002222184
MolPort-003-983-431
MolPort-004-905-001
MolPort-004-955-161
NCGC00025056-02
NChemBio.2007.10-comp19
NK 171
NSC 141540
NSC-141540
NSC141540
Prestwick0_000396
Prestwick1_000396
Prestwick2_000396
Prestwick3_000396
Prestwick_211
S1225_Selleck
SAM001246880
SMR000112002
SPBio_002532
ST056353
Toposar
UNII-6PLQ3CP4P3
VP 16
VP 16 (pharmaceutical)
VP 16-213
VP 16213
VP-16
VP-16-213
VePESID (TN)
VePesid
Vepesid
Vepesid J
Vepeside
ZINC03830818
ZINC03938684
Zuyeyidal
etoposide
nchembio.573-comp8
nchembio873-comp2
trans-Etoposide
30
PaclitaxelapprovedPhase 3, Phase 2262133069-62-436314
Synonyms:
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
157069-30-2
33069-62-4
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.
7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.
7-Epi-Paclitaxel
7-Epi-Taxol
7-Epipaclitaxel
7-Epitaxol
7-epi-Paclitaxel
7-epi-Taxol
AB00513812
ABI 007
ABI-007
ABI007
AC-675
AC1L1IOG
AC1L1VJI
AC1L9AVF
ACon1_002231
ANX-513
Abraxane
Abraxane (TN)
Abraxane I.V. Suspension
Abraxis BioScience brand of albumin-bound paclitaxel
Ambotz33069-62-4
Anzatax
Asotax
BIDD:PXR0046
BMS 181339-01
BMS-181339
BMS-181339-01
BPBio1_000320
BRD-A23723433-001-01-2
BRD-A28746609-001-04-0
BRD-K62008436-001-03-1
BSPBio_000290
BSPBio_001152
BSPBio_002614
Bio-0076
Bio1_000362
Bio1_000851
Bio1_001340
Bio2_000416
Bio2_000896
Bristaxol
C07394
C466458
C47H51NO14
CCRIS 8143
CHEBI:103439
CHEBI:45863
CHEMBL100910
CHEMBL418410
CHEMBL48
CID36314
CID441276
CID4666
CID6713921
CID6915727
CPD-8718
Capxol
D00491
DB01229
DHP-107
DHP-208
DRG-0190
DTS-301
DivK1c_000441
EU-0101201
Ebetaxel
EmPAC
Epitaxol
Genaxol
Genetaxyl
Genexol
Genexol-PM
HMS1362J13
HMS1568O12
HMS1792J13
HMS1922K08
HMS1990J13
HMS2090D07
HMS2093K15
HMS501G03
HSDB 6839
I06-0014
IDI1_000441
IDI1_002171
Intaxel
KBio1_000441
KBio2_000492
KBio2_002016
KBio2_002509
KBio2_003060
KBio2_004584
KBio2_005077
KBio2_005628
KBio2_007152
KBio2_007645
KBio3_000903
KBio3_000904
KBio3_001834
KBio3_002987
KBioGR_000492
KBioGR_001893
 
KBioGR_002509
KBioSS_000492
KBioSS_002016
KBioSS_002517
LMPR0104390001
LS-31070
LipoPac
Lopac0_001201
MBT 0206
MEGxp0_001940
MLS000863266
MLS001077297
MLS002154218
MLS002172439
MLS002695976
MPI-5018
Micellar Paclitaxel
Mitotax
MolPort-001-742-627
MolPort-003-665-783
MolPort-003-932-365
NCGC00024995-02
NCGC00024995-03
NCGC00024995-04
NCGC00024995-05
NCGC00024995-06
NCGC00024995-07
NCGC00164367-01
NCGC00164367-02
NCGC00164367-03
NCI60_000601
NINDS_000441
NK 105
NP-010981
NSC 125973
NSC-125973
NSC125973
NSC358882
Nanotaxel
Neuro_000060
Nova-12005
OAS-PAC-100
OncoGel
Onxal
Onxol
Onxol, Taxol, Nov-Onxol, Paclitaxel
P1632
Paclical
Pacligel
Paclitaxel
Paclitaxel (JAN/USP)
Paclitaxel (JAN/USP/INN)
Paclitaxel (Taxol)
Paclitaxel [USAN:INN:BAN]
Paxceed
Paxene
Paxoral
Plaxicel
Praxel
Prestwick0_000155
Prestwick1_000155
Prestwick2_000155
Prestwick3_000155
Probes2_000350
QW 8184
S-8184 Paclitaxel Injectable Emulsion
S1150_Selleck
SDCCGMLS-0066823.P001
SDP-013
SMP1_000228
SMR000394086
SMR000857385
SPBio_000943
SPBio_002229
SPECTRUM1503908
ST50306996
Spectrum2_000872
Spectrum3_001057
Spectrum4_001197
Spectrum5_001491
Spectrum_001536
T 7402
T1912_SIGMA
T7191_SIGMA
T7402_SIGMA
TA1
TAXOL (TN)
TAXOL, 10-EPI,
TXL
TaxAlbin
Taxol
Taxol A
Taxol Konzentrat
Taxol.RTM. (Registered Trademark)
UNII-P88XT4IS4D
UPCMLD-DP108:001
UPCMLD-DP108:002
Vascular Wrap
Xorane
Yewtaxan
abi-007
albumin-bound paclitaxel
cMAP_000068
nchembio.188-comp1
nchembio.2007.34-comp9
nchembio.215-comp9
nchembio853-comp6
paclitaxel
weekly paclitaxel
31
ZidovudineapprovedPhase 2, Phase 3, Phase 149130516-87-135370
Synonyms:
-Azido-3&prime
-deoxythymidine
1-(3-Azido-2,3-dideoxy-beta-D-ribofuranosyl)thymine
3&prime
3' Azido 2',3' Dideoxythymidine
3' Azido 3' deoxythymidine
3'-Azido-2',3'-Dideoxythymidine
3'-Azido-3'-deoxythymidine
3'-Azido-3'-deoxythymidine & Concanavalin A
3'-Azido-3'-deoxythymidine & Erythropoietin
3'-Azido-3'-deoxythymidine & Heteropolyoxotungstate PM-19
3'-Azido-3'-deoxythymidine & Interleukin-1
3'-Azido-3'-deoxythymidine & Interleukin-2
3'-Azido-3'-deoxythymidine & Interleukin-6
3'-Azido-3'-deoxythymidine & Lithium & Erythropoietin
3'-Azido-3'-deoxythymidine & Lithium & Interleukin-1
3'-Azido-3'-deoxythymidine & Lithium & Interleukin-6
3'-Azido-3'-deoxythymidine & Lymphoblastoid Interferon
3'-Azido-3'-deoxythymidine & Sho-Saiko-To
3'-Azido-3'-deoxythymidine (AIDS)
3'-Azido-3'deoxythymidine & Interferon .alpha.
3'-Azidothymidine
3'-Deoxy-3'-azidothymidine
3'-azido-3'-deoxythymidine, AZT
3-Azido-3-deoxythymidine
30516-87-1
399024-19-2
A2169_SIGMA
AC1L1TKL
AC1Q2OEK
AZT
AZT & CD4(178)-PE 40
AZT & Colony-stimulating factor 2
AZT & Concanavalin A (ConA)
AZT & EPO
AZT & GM-CSF
AZT & HPA
AZT & IFN.alpha.
AZT & IL-1
AZT & IL-2
AZT & IL-6
AZT & Interferon-.alpha.-2
AZT & Li & EPO
AZT & Li & GM-CSF
AZT & Li & IL-1
AZT & Li & IL-6
AZT & Lymphoblastoid Interferon
AZT & NP (from PHCA or HSA)
AZT & PM-19
AZT & SST
AZT & rIFN.alpha.2
AZT & rsCD4 & rIFN.alpha.A
AZT & rsT4
AZT & sCD4
AZT & srCD4
AZT (Antiviral)
AZT Antiviral
AZT TRANSPLACENTAL CARCINOGENESIS STUDY
AZT+PRO 140
AZT, Antiviral
Antiviral AZT
Apo-Zidovudine
Azidothymidine
Aztec
BB_NC-1012
BPBio1_000403
BRD-K72903603-001-04-6
BSPBio_000365
BSPBio_003153
BW A509U
BW-A 509U
BW-A-509U
BW-A509U
BWA 509U
BWA-509U
BWA509U
C07210
CCRIS 105
CHEBI:10110
CHEBI:127307
CHEMBL129
CID35370
CPD000058351
 
Compound S
Cpd S
D00413
D015215
DB00495
DRG-0004
DS-4152 & AZT
DivK1c_000524
HMS1921J20
HMS2090G11
HMS2092D06
HMS501K06
HSDB 6515
IDI1_000524
Interferon AD + 3'-azido-3'-deoxythymidine
Intron A & AZT
K7 [P Ti2 W10 O40]
KBio1_000524
KBio2_001828
KBio2_004396
KBio2_006964
KBio3_002653
KBioGR_000703
KBioSS_001828
LS-1159
Liposomal AZT-SN-1
Liposomal AZT-SN-3
MLS000028548
MLS001055351
MLS001076358
MLS002153202
MLS002222249
Met-SDF-1.beta. & AZT
Met-SDF-1.beta. & Zidovudine
MolPort-002-507-286
NCGC00023945-03
NCGC00023945-04
NCGC00023945-05
NCGC00023945-08
NCGC00178237-01
NCGC00178237-02
NINDS_000524
NSC 602670
Novo-Azt
PC-SOD+AZT
Prestwick3_000333
Propolis+AZT
Racemic Liposomal AZT
Retrovir
Retrovir (TN)
Retrovir(TM)
SAM002548971
SMR000058351
SN-1-dipalmitoylglycerophospho-AZT (in a lipid vesicle)
SN-3-dipalmitoylglycerophospho-AZT (in a lipid vesicle)
SPBio_000834
SPECTRUM1502109
STK801891
Spectrum2_000927
Spectrum3_001507
Spectrum4_000332
Spectrum5_001101
Spectrum_001348
UNII-4B9XT59T7S
ZDV
ZIDOVUDINE [AZT]
ZINC03779042
ZVD
Zidovudin
Zidovudina
Zidovudina [Spanish]
Zidovudine
Zidovudine (JAN/USP/INN)
Zidovudine EP III
Zidovudine [USAN:INN:BAN:JAN]
Zidovudine+PRO 140
Zidovudinum
Zidovudinum [Latin]
antiviral
azidodeoxythymidine
rIFN-beta seron & AZT
racemic-dipalmitoylglycerophospho-AZT (in a lipid vesicle)
zidovudin
zidovudine
32
MeloxicamapprovedPhase 37571125-38-75281106, 54677470
Synonyms:
(3E)-3-[hydroxy-[(5-methyl-1,3-thiazol-2-yl)amino]methylidene]-2-methyl-1,1-dioxo-1
133687-22-6
2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-(5-methylthiazolyl)-, 1,1-dioxide
4-Hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide
4-Hydroxy-2-methyl-N-(5-methyl-2-thiazoyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide
4-hydroxy-2-mehtyl-N-(5-mehtyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide
4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide
4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide
71125-38-7
AC-1325
AC1NQY12
AC1Q3XZW
AKOS000279442
Abbott brand of meloxicam
Almirall brand of meloxicam
Apo-meloxicam
Bio-0826
Boehringer Ingelheim brand of meloxicam
C065757
C08169
C14H13N3O4S2
CCRIS 9139
CHEMBL599
CID5281106
Co Meloxicam
D00969
DB00814
Dom-meloxicam
Europharma brand of meloxicam
FT-0082769
Gen-meloxicam
HMS1922D19
HMS2089B18
I06-0490
LS-40538
M1959
Masflex
 
Meloxicam
Meloxicam (JAN/USAN/INN)
Meloxicam [USAN:BAN:INN]
Meloxicamum
Meloxicamum [Latin]
Meloxicamum [latin]
Meloxivet
Metacam
Mobec
Mobic
Mobic (TN)
Mobic, Metacam, Parocin, Meloxicam
Mobicox
MolPort-002-885-839
Movalis
Movatec
Movicox
Méloxicam
Novo-meloxicam
PHL-meloxicam
PMS-meloxicam
Parocin
Promeco brand of meloxicam
Ratio-meloxicam
S1734_Selleck
SPECTRUM1504150
STK620505
Squibb brand of meloxicam
TL8005001
Tenaron
UH-AC 62XX
UHAC-62XX
UNII-VG2QF83CGL
UNII-vg2qf83cgl
Uticox
meloxicam
miloxicam
reumoxicam
33
PrednisoneapprovedPhase 3, Phase 2, Phase 1126753-03-25865
Synonyms:
(1S,2R,10S,11S,14R,15S)-14-hydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-5,17-dione
(8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione
(8xi,9xi,14xi)-17,21-dihydroxypregna-1,4-diene-3,11,20-trione
.delta. E
.delta.(sup1)-Cortisone
.delta.-Cortelan
.delta.-Cortisone
.delta.-Cortone
.delta.-E
.delta.1-Cortisone
.delta.1-Dehydrocortisone
.delta.sone
1,2-Dehydrocortisone
1,4-Pregnadiene-17-alpha,21-diol-3,11,20-trione
1,4-Pregnadiene-17.alpha.,21-diol-3,11,20-trione
1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione
1-Cortisone
1-Dehydrocortisone
17,21-Dihydroxypregna-1,4-diene-3,11,20-trione
17alpha,21-Dihydroxy-1,4-pregnadiene-3,11,20-trione
53-03-2
68-59-7
81552_FLUKA
AC-11112
AC1L1LB2
AC1Q29EZ
ACon0_000082
ACon1_000297
AI3-52939
Adasone
Ancortone
Apo-Prednisone
Apo-prednisone
BPBio1_000323
BRD-K85883481-001-04-2
BSPBio_000293
Betapar
Bicortone
Bio-0649
C07370
C21H26O5
CCRIS 2646
CHEBI:8382
CHEMBL635
CID5865
CPD001227202
Cartancyl
Colisone
Cortan
Cortancyl
Cortidelt
Cotone
DB00635
Dacorten
Dacortin
Decortancyl
Decortin
Decortisyl
Dehydrocortisone
Dekortin
Delcortin
Dellacort
Dellacort A
Delta Cortelan
Delta E
Delta E.
Delta-Cortelan
Delta-Dome
Delta-cortelan
Delta-cortisone
Delta-cortone
Delta-dome
Deltacortene
Deltacortisone
Deltacortone
Deltasone
Deltasone, Liquid Pred, Orasone, Adasone, Deltacortisone,Prednisone
Deltison
Deltisona
Deltisone
Deltra
Di-Adreson
Diadreson
EINECS 200-160-3
Econosone
Encorton
Encortone
Enkortolon
Enkorton
Fernisone
Fiasone
HMS1568O15
HMS2090J13
HSDB 3168
Hostacortin
In-Sone
Incocortyl
Juvason
 
Kortancyl
LMST02030180
LS-1325
Liquid Pred
Lisacort
Lodotra
MEGxm0_000443
MLS001061265
MLS001304073
MLS001335907
MLS001335908
MLS002154191
MLS002207083
Me-Korti
Metacortandracin
Meticorten
Meticorten (Veterinary)
Metrevet (Veterinary)
MolPort-001-740-041
NCGC00090766-01
NCGC00090766-02
NCGC00090766-03
NCI-C04897
NCI60_000008
NSC 10023
NSC10023
Nisona
Nizon
Novoprednisone
Nurison
Orasone
Origen Prednisone
P1276
P6254_SIGMA
PRD
Panafcort
Panasol
Paracort
Parmenison
Pehacort
Perrigo Prednisone
Precort
Predeltin
Prednicen-M
Prednicorm
Prednicort
Prednicot
Prednidib
Prednilonga
Prednison
Prednisona
Prednisona [INN-Spanish]
Prednisone
Prednisone Intensol
Prednisone [INN:BAN]
Prednisonum
Prednisonum [INN-Latin]
Prednitone
Prednizon
Prednovister
Presone
Prestwick0_000077
Prestwick1_000077
Prestwick2_000077
Prestwick3_000077
Prestwick_405
Pronison
Pronisone
Rayos
Rectodelt
Retrocortine
S1622_Selleck
SAM002264641
SK-Prednisone
SMR000718760
SMR001227202
SPBio_002214
Servisone
Sone
Sterapred
Supercortil
U 6020
UNII-VB0R961HZT
Ultracorten
Ultracortene
WLN: L E5 B666 CV OV AHTTT&J A1 E1 FV1Q FQ
Winpred
Wojtab
ZINC03875357
Zenadrid
Zenadrid (veterinary)
Zenadrid [veterinary]
delta cortelan
delta(sup 1)-Cortisone
delta(sup 1)-Dehydrocortisone
delta-1-Cortisone
delta-1-Dehydrocortisone
delta-Cortisone
delta-Cortone
34Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 3, Phase 1, Phase 29988
35HormonesPhase 3, Phase 1, Phase 211748
36Hormone AntagonistsPhase 3, Phase 1, Phase 210002
37AnalgesicsPhase 3, Phase 2, Phase 19358
38Analgesics, Non-NarcoticPhase 3, Phase 2, Phase 15184
39Albumin-Bound PaclitaxelPhase 3, Phase 22621
40Peripheral Nervous System AgentsPhase 3, Phase 2, Phase 118510
41Antineoplastic Agents, PhytogenicPhase 3, Phase 2, Phase 14294
42glucocorticoidsPhase 3, Phase 1, Phase 23896
43Antirheumatic AgentsPhase 3, Phase 2, Phase 18496
44Antineoplastic Agents, HormonalPhase 3, Phase 1, Phase 24256
45Tubulin ModulatorsPhase 3, Phase 2, Phase 14279
46AntimetabolitesPhase 2, Phase 3, Phase 19454
47Antibiotics, AntitubercularPhase 3, Phase 2, Phase 15971
48Topoisomerase InhibitorsPhase 3, Phase 2, Phase 14081
49Anti-Inflammatory AgentsPhase 3, Phase 1, Phase 28478
50Etoposide phosphatePhase 3, Phase 2, Phase 11169

Interventional clinical trials:

(show top 50)    (show all 151)
idNameStatusNCT IDPhase
1HIV/AIDS Kaposis Sarcoma: Comparison of Response to HAART vs HAART Plus CXTCompletedNCT00380770Phase 4
2Anti-Retrovirals for Kaposi's SarcomaCompletedNCT00444379Phase 4
3Organ Transplant Infection Prevention and Detection ProjectCompletedNCT00177801Phase 4
4Valganciclovir to Treat HHV-8 Associated Multicentric Castleman's DiseaseWithdrawnNCT00361933Phase 4
5Paclitaxel Compared With Doxorubicin in Treating Patients With Advanced AIDS-Related Kaposi's SarcomaCompletedNCT00003350Phase 3
6A Pilot Study Of the Effects of Highly Active Antiretroviral Therapy on Kaposi's Sarcoma in ZimbabweCompletedNCT00834457Phase 2, Phase 3
7Doxorubicin in Treating Patients With AIDS-Related Kaposi's SarcomaCompletedNCT00002985Phase 3
8A Study of DOX-SL in the Treatment of AIDS-Related Kaposi's SarcomaCompletedNCT00002319Phase 3
9Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL ) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma.CompletedNCT00002147Phase 3
10Safety and Effectiveness of an Experimental Drug, IM862, in Treating Kaposi's Sarcoma in AIDS PatientsCompletedNCT00002445Phase 3
11A Study of AZT in HIV-Infected Patients With AIDS-Related Kaposi's SarcomaCompletedNCT00000994Phase 3
12Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's SarcomaCompletedNCT00002105Phase 3
13A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With Adriamycin/Bleomycin/Vincristine (ABV) in the Treatment of HIV-Associated Kaposi's Sarcoma.CompletedNCT00002093Phase 3
14Three Chemo Regimens as an Adjunct to ART for Treatment of Advanced AIDS-KSRecruitingNCT01435018Phase 3
15Preventing TB-IRIS in High-risk Patients: a Randomized Placebo-controlled Trial of PrednisoneRecruitingNCT01924286Phase 3
16TB-IRIS NSAID Cox-2 Inhibitor Prevention TrialRecruitingNCT02060006Phase 3
17Antiretroviral Therapy (ART) Alone or With Delayed Chemo Versus ART With Immediate Chemo for Limited AIDS-related Kaposi's SarcomaActive, not recruitingNCT01352117Phase 3
18A Comparison of DOX-SL Versus Adriamycin Plus Bleomycin Plus Vincristine in the Treatment of Severe AIDS-Related Kaposi's SarcomaActive, not recruitingNCT00002318Phase 3
19Bevacizumab to Treat Kaposi's Sarcoma in HIV-Positive and HIV-Negative PatientsCompletedNCT00055237Phase 2
20Interleukin-12 in Treating Patients With AIDS-Related Kaposi's SarcomaCompletedNCT00019188Phase 1, Phase 2
21Intralesional Bevacizumab for Treating AIDS-associated Kaposi´s Sarcoma of the Larynx, Pharynx and Oral CavityCompletedNCT01296815Phase 2
22Halofuginone Hydrobromide in Treating Patients With HIV-Related Kaposi's SarcomaCompletedNCT00064142Phase 2
23Treatment of Classical Non-HIV-Related Kaposi's Sarcoma With the Antiviral Drug IndinavirCompletedNCT00362310Phase 2
24Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's SarcomaCompletedNCT00090987Phase 2
25Antiviral Therapy in Treating Patients With Kaposi's Sarcoma With or Without HIV InfectionCompletedNCT00019240Phase 2
26Nicotine Skin Patch in Treating Patients With Kaposi's SarcomaCompletedNCT00295984Phase 2
27BMS-275291 in Treating Patients With HIV-Related Kaposi's SarcomaCompletedNCT00024024Phase 1, Phase 2
28SU5416 in Treating Patients With AIDS-Related Kaposi's SarcomaCompletedNCT00005042Phase 2
29Paclitaxel in Treating Patients With AIDS-Related Kaposi's SarcomaCompletedNCT00003008Phase 2
30Liposomal Doxorubicin and Interleukin-12 in Treating Patients With AIDS-Related Kaposi's SarcomaCompletedNCT00020449Phase 2
31Thalidomide in Treating Patients With HIV-Associated Kaposi's SarcomaCompletedNCT00019123Phase 2
32Suppression of Oral HHV8 Shedding With ValganciclovirCompletedNCT00194467Phase 2
33Evaluation of Technetium Tc 99m Tilmanocept (Lymphoseek®) Localization, Retention, and Distribution in Primary Cutaneous Kaposi's Sarcoma (KS) and Lymphatic Drainage From KS Lesions by SPECT and SPECT/CT ImagingCompletedNCT02201420Phase 2
34The Safety and Effectiveness of Interferon Alfa-2B Plus Didanosine in Patients With Kaposi's SarcomaCompletedNCT00001114Phase 2
35A Study of ALRT1057 in Patients With AIDS-Related Kaposi's SarcomaCompletedNCT00002188Phase 2
36A Pilot Study of OPC-8212 (Vesnarinone) in Persons With AIDS-Related Kaposi's SarcomaCompletedNCT00002131Phase 2
37A Study of Targretin Capsules in Patients With AIDS-Related Kaposi's SarcomaCompletedNCT00002212Phase 2
38The Safety and Effectiveness of Ritonavir in the Treatment of HIV-Related Kaposi's SarcomaCompletedNCT00002366Phase 2
39Phase II Study of Intravenous Novantrone(R) in the Treatment of AIDS Related Kaposi's SarcomaCompletedNCT00002259Phase 2
40SU5416 in Patients With AIDS-Related Kaposi's Sarcoma Who Have Not Responded to TreatmentCompletedNCT00005931Phase 2
41A Study of Ro 24-7429 in Patients With HIV-Related Kaposi's SarcomaCompletedNCT00002314Phase 2
42A Study of Doxorubicin in the Treatment of AIDS-Related Kaposi's SarcomaCompletedNCT00000996Phase 2
43Photodynamic Therapy Clinical Trial For Cutaneous AIDS-Related Kaposi's Sarcoma Study Summary.CompletedNCT00002167Phase 2
44Paclitaxel in Advanced Refractory Kaposi's Sarcoma (AIDS-KS): A Phase II Trial of Paclitaxel From Baker Norton PharmaceuticalsCompletedNCT00002189Phase 2
45Phase II Evaluation of Low-Dose Oral Etoposide for the Treatment of Relapsed or Progressed AIDS-Related Kaposi's Sarcoma After Systemic ChemotherapyCompletedNCT00000807Phase 2
46Comparison of Liposomal Doxorubicin Used Alone or in Combination With Bleomycin Plus Vincristine in the Treatment of Kaposi's Sarcoma in Patients With AIDSCompletedNCT00001059Phase 2
47Phase II Study of Zidovudine and Recombinant Alpha-2A Interferon in the Treatment of Patients With AIDS-Associated Kaposi's SarcomaCompletedNCT00000687Phase 2
48Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic SarcomaCompletedNCT01154452Phase 1, Phase 2
49Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent SarcomasCompletedNCT00474994Phase 2
50A Pilot, Open-Label, Phase II, Randomized Study to Determine the Effects of Viracept on the Outcome of Cutaneous and Mucosal KS in AIDS Patients With CD4 <= 500 Cells/mm3CompletedNCT00002185Phase 2

Search NIH Clinical Center for Kaposi Sarcoma

Inferred drug relations via UMLS65/NDF-RT43:


Cochrane evidence based reviews: sarcoma, kaposi

Genetic Tests for Kaposi Sarcoma

About this section

Anatomical Context for Kaposi Sarcoma

About this section

MalaCards organs/tissues related to Kaposi Sarcoma:

33
Skin, Lung, Lymph node, Prostate, Liver, Heart, B cells

Animal Models for Kaposi Sarcoma or affiliated genes

About this section

MGI Mouse Phenotypes related to Kaposi Sarcoma:

38
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053709.8CDK6, FLT4, HGF, IL6, IL6R, IL6ST
2MP:00020069.8CD34, CDK6, FGF2, IL6, IL6R, IL6ST
3MP:00053699.7CDK6, FGF2, FLT4, IL6, KDR, PDPN
4MP:00107719.4CD34, FGF5, FLT4, IL6, IL6ST, KDR
5MP:00053859.2CDK6, FGF2, FLT4, HGF, IL6, IL6ST
6MP:00053978.9CD34, CDK6, FGF2, HGF, IL6, IL6R
7MP:00053878.6CCR8, CD34, CDK6, FLT4, IL6, IL6R

Publications for Kaposi Sarcoma

About this section

Articles related to Kaposi Sarcoma:

(show top 50)    (show all 277)
idTitleAuthorsYear
1
Under the Weather: Legionellosis and Meteorological Factors. (26993637)
2016
2
Tramadol-related psychosis in a patient with bipolar I disorder. (25603153)
2015
3
YKL-40 expression in soft-tissue sarcomas and atypical lipomatous tumors. An immunohistochemical study of 49 tumors. (24650028)
2014
4
Fetal complications due to intrahepatic cholestasis of pregnancy. (25153210)
2014
5
Kinesin family deregulation coordinated by bromodomain protein ANCCA and histone methyltransferase MLL for breast cancer cell growth, survival and tamoxifen resistance. (24391143)
2014
6
Human Papillomavirus-Associated Oropharynx Cancer (HPV-OPC): Treatment Options. (25240410)
2014
7
VACTERL (Vertebral Defects, Anal Atresia, Tracheoesophageal Fistula withA Esophageal Atresia, Cardiac Defects, Renal and Limb Anomalies) Association: Disease Spectrum in 25 Patients Ascertained for Their UpperA Limb Involvement. (24210691)
2013
8
Progressive optic nerve collateralization after serial intravitreal ranibizumab injections for central retinal vein occlusion. (23190926)
2013
9
Laparoscopic treatment for esophageal achalasia: experience at a single center. (24091178)
2013
10
The risk of amenorrhea is related to chemotherapy-induced leucopenia in breast cancer patients receiving epirubicin and taxane based chemotherapy. (22615953)
2012
11
Study of the common genetic background for rheumatoid arthritis and systemic lupus erythematosus. (21068098)
2011
12
Effects of apelin and vascular endothelial growth factor on central retinal vein occlusion in monkey eyes intravitreally injected with bevacizumab: a preliminary study. (21552499)
2011
13
Probing binding determinants in center P of the cytochrome bc(1) complex using novel hydroxy-naphthoquinones. (19660431)
2010
14
BRCA1 affects global DNA methylation through regulation of DNMT1. (20820192)
2010
15
Cognitive behavioral group therapy for social phobia with or without attention training: a controlled trial. (19059753)
2009
16
Retroperitoneal leiomyomata as a cause of bilateral hydronephrosis and lumbosciatic pain. (22162734)
2009
17
The effects of a motor and a cognitive concurrent task on walking in children with developmental coordination disorder. (18809330)
2009
18
Characterization of five novel large deletions causing hereditary haemorrhagic telangiectasia. (18312453)
2008
19
Abolishment of pleural effusion as the initial manifestation of chronic myelomonocytic leukemia without chemotherapy. (19039201)
2008
20
Ectopic cyclin D1 overexpression increases chemosensitivity but not cell proliferation in multiple myeloma. (19020753)
2008
21
Effects of high-fructose corn syrup and sucrose consumption on circulating glucose, insulin, leptin, and ghrelin and on appetite in normal-weight women. (17234503)
2007
22
Plasma D-dimer levels in patients with typhoid fever. (18041311)
2007
23
A generally applicable method for assessing the electrophilicity and reactivity of diverse nitrile-containing compounds. (17157022)
2007
24
Caspase-3 and caspase-6 in ductal breast carcinoma: a descriptive study. (16977583)
2006
25
Study of the PVRL1 gene in Italian nonsyndromic cleft lip patients with or without cleft palate. (16674562)
2006
26
Differential effects of anesthetics on endotoxin-induced liver injury. (15824646)
2005
27
Reply: limbal stem cell deficiency: a clinical chamaelon. (15359232)
2005
28
Hypertension attenuates cell-to-cell communication in hamster retractor muscle feed arteries. (15486033)
2005
29
Matrix metalloproteinase-9 contributes to human atrial remodeling during atrial fibrillation. (14998623)
2004
30
Suppression of the biological activities of the epidermal growth factor (EGF)-like domain by the heparin-binding domain of heparin-binding EGF-like Growth Factor. (15331606)
2004
31
Dictyostelium stress-activated protein kinase alpha, a novel stress-activated mitogen-activated protein kinase kinase kinase-like kinase, is important for the proper regulation of the cytoskeleton. (14593072)
2003
32
Role of hepatitis B virus genotypes in chronic hepatitis B exacerbation. (12905145)
2003
33
Human heparanase: a molecular determinant of brain metastasis. (11384754)
2001
34
Differential regulation of Rho and Rac through heterotrimeric G-proteins and cyclic nucleotides. (11560922)
2001
35
Japanese X-linked juvenile retinoschisis: conflict of phenotype and genotype with novel mutations in the XLRS1 gene. (11594966)
2001
36
Pathological, immunohistochemical and bacteriological findings in kidneys of cattle with contagious bovine pleuropneumonia (CBPP). (11222005)
2001
37
New insights into the pathogenesis of intestinal dysfunction: secretory diarrhea and cystic fibrosis. (11830825)
2000
38
The role of aquaporins in cellular and whole plant water balance. (10748263)
2000
39
The lectin domain of UDP-N-acetyl-D-galactosamine: polypeptide N- acetylgalactosaminyltransferase-T4 directs its glycopeptide specificities. (10984485)
2000
40
Neonatal hypothyroidism: treatment and outcome. (10037081)
1999
41
Xanthogranulomatous pyelonephritis: urinary and fine needle aspiration cytology. (9684612)
1998
42
The ovary is not a major source of placental protein 14 (glycodelin). (9886526)
1998
43
Altered patterns of subchondral bone mineralization in KienbAPck's disease. (9061515)
1997
44
TNF-alpha regulates GM-CSF-, IL-3- or M-CSF-induced Fc epsilon RII/CD23 gene expression and soluble Fc epsilon RII release by human monocytes. (9122614)
1997
45
Inhibitory effect of magnesium L-ascorbyl-2-phosphate (VC-PMG) on melanogenesis in vitro and in vivo. (8543691)
1996
46
Receptors that turn on and turn off natural killer cells. (8820783)
1996
47
In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. (7562048)
1995
48
Interleukin-6 in psoriasis: expression and mitogenicity studies. (1294020)
1992
49
Cloning of human airway 15-lipoxygenase: identity to the reticulocyte enzyme and expression in epithelium. (1566855)
1992
50
Correlation of cell migration, cell invasion, receptor number, proteinase production, and basic fibroblast growth factor levels in endothelial cells. (2404994)
1990

Variations for Kaposi Sarcoma

About this section

Cosmic variations for Kaposi Sarcoma:

7
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Conf
1COSM575NRASsoft tissue,skin,sarcoma,NS3
2COSM575NRASsoft tissue,skin,sarcoma,NS3
3COSM575NRASsoft tissue,skin,sarcoma,NS3
4COSM520KRASsoft tissue,lung,sarcoma,NS3
5COSM520KRASsoft tissue,lung,sarcoma,NS3
6COSM520KRASsoft tissue,lung,sarcoma,NS3

Expression for genes affiliated with Kaposi Sarcoma

About this section
Search GEO for disease gene expression data for Kaposi Sarcoma.

Pathways for genes affiliated with Kaposi Sarcoma

About this section

Pathways related to Kaposi Sarcoma according to GeneCards Suite gene sharing:

(show all 43)
idSuper pathwaysScoreTop Affiliating Genes
110.1IFNA1, IFNA2, IL6
210.1IFNA1, IFNA2, IL6
310.1CD34, IFNA2, IL6
410.1FGF2, KDR, VEGFA
510.1FGF2, KDR, VEGFA
610.1FGF2, KDR, VEGFA
7
Show member pathways
10.1FLT4, KDR, VEGFA
810.1FGF2, FGF4, VEGFA
9
Show member pathways
10.1IL6, IL6R, IL6ST
1010.1IL6, IL6R, IL6ST
11
Show member pathways
10.1IL6, IL6R, IL6ST
1210.1IL6, IL6R, IL6ST
13
Show member pathways
10.1IL6, IL6R, IL6ST
14
Show member pathways
10.1FGF2, FGF4, FGF5
15
Show member pathways
10.1FGF2, FGF4, FGF5
1610.1CD34, IL6, IL6R
1710.1IL6ST, OSM, VEGFA
1810.0HGF, IL6, KDR, VEGFA
19
Show member pathways
10.0FGF2, FLT4, KDR, VEGFA
2010.0CD34, FGF2, FGF4, IL6
21
Show member pathways
10.0IL6, IL6R, IL6ST, OSM
229.9FGF2, HGF, IL6, KDR, VEGFA
239.8IFNA1, IFNA2, IL6, IL6R, IL6ST
24
Show member pathways
9.8CDK6, FLT4, HGF, IL6, KDR, VEGFA
259.8FGF2, FGF4, HGF, IL6, KDR, VEGFA
26
Show member pathways
9.8CDK6, FGF2, FGF4, FGF5, HGF, IL6
279.7FGF2, FGF4, FGF5, FLT4, KDR, VEGFA
28
Show member pathways
9.7FGF2, FGF4, FGF5, FLT4, KDR, VEGFA
29
Show member pathways
9.7IFNA1, IFNA2, IL6, IL6R, IL6ST, OSM
309.7CDK6, FGF2, FGF4, FGF5, HGF, IL6
31
Show member pathways
9.7FGF2, FGF4, FGF5, FLT4, HGF, IL6
32
Show member pathways
9.7FGF2, FGF4, FGF5, FLT4, HGF, IL6
33
Show member pathways
9.7FGF2, FGF4, FGF5, FLT4, HGF, IL6
34
Show member pathways
9.7FGF2, FGF4, FGF5, FLT4, HGF, IL6
35
Show member pathways
9.5FGF2, FGF4, FGF5, FLT4, HGF, IL6
36
Show member pathways
9.5FGF2, FGF4, FGF5, FLT4, HGF, IL6
37
Show member pathways
9.2CCR8, FGF2, FGF4, FGF5, FLT4, HGF
38
Show member pathways
9.2CCR8, FGF2, FGF4, FGF5, FLT4, HGF
39
Show member pathways
9.2FGF2, FGF4, FGF5, FLT4, HGF, IFNA1
40
Show member pathways
9.1CCR8, FLT4, HGF, IFNA1, IFNA2, IL6
41
Show member pathways
9.1CD34, FGF2, FGF4, FGF5, HGF, IFNA1
42
Show member pathways
9.0CCR8, CDK6, FGF2, FGF4, FGF5, FLT4
438.9CDK6, FGF2, FGF4, FGF5, FLT4, HGF

GO Terms for genes affiliated with Kaposi Sarcoma

About this section

Biological processes related to Kaposi Sarcoma according to GeneCards Suite gene sharing:

(show all 32)
idNameGO IDScoreTop Affiliating Genes
1hepatic immune responseGO:000238411.0IL6, IL6R
2chondroblast differentiationGO:006059110.9FGF2, FGF4
3regulation of endothelial cell chemotaxis to fibroblast growth factorGO:200054410.9FGF2, FGF4
4positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathwayGO:003803310.9KDR, VEGFA
5negative regulation of collagen biosynthetic processGO:003296610.9IL6, IL6R
6endothelium developmentGO:000315810.8CD34, KDR
7positive regulation of cellular component movementGO:005127210.8PDPN, VEGFA
8glial cell differentiationGO:001000110.8FGF2, FGF5
9positive regulation of blood vessel endothelial cell migrationGO:004353610.8FGF2, VEGFA
10cell migration involved in sprouting angiogenesisGO:000204210.8FGF2, KDR, VEGFA
11cellular response to hepatocyte growth factor stimulusGO:003572910.6HGF, IL6
12phosphatidylinositol-mediated signalingGO:004801510.6FGF2, FGF4, FGF5
13phosphatidylinositol-3-phosphate biosynthetic processGO:003609210.6FGF2, FGF4, FGF5
14peptidyl-tyrosine phosphorylationGO:001810810.6FGF2, FLT4, KDR
15positive regulation of peptidyl-serine phosphorylationGO:003313810.5IL6, OSM, VEGFA
16positive chemotaxisGO:005091810.5FGF2, HGF, VEGFA
17positive regulation of smooth muscle cell proliferationGO:004866110.5FGF2, IL6, IL6R
18positive regulation of ERK1 and ERK2 cascadeGO:007037410.5FGF2, FLT4, IL6
19positive regulation of cell divisionGO:005178110.5FGF2, FGF4, FGF5, VEGFA
20positive regulation of tyrosine phosphorylation of Stat3 proteinGO:004251710.4IFNA2, IL6, IL6R, IL6ST, OSM
21positive regulation of MAPK cascadeGO:004341010.4FLT4, IL6, KDR, OSM
22positive regulation of protein phosphorylationGO:000193410.4FGF2, FGF4, VEGFA
23positive regulation of peptidyl-tyrosine phosphorylationGO:005073110.3HGF, IL6, IL6R, OSM, VEGFA
24positive regulation of osteoblast differentiationGO:004566910.3FGF2, HGF, IL6, IL6R, IL6ST
25cytokine-mediated signaling pathwayGO:001922110.3IFNA1, IFNA2, IL6, IL6R, IL6ST
26blood coagulationGO:000759610.2HGF, IFNA1, IFNA2, SLC7A11, VEGFA
27positive regulation of angiogenesisGO:004576610.1CD34, FGF2, HGF, KDR, VEGFA
28vascular endothelial growth factor receptor signaling pathwayGO:004801010.0FGF2, FGF4, FGF5, FLT4, VEGFA
29positive regulation of gene expressionGO:00106289.9CDK6, FGF2, FGF4, IL6, VEGFA
30negative regulation of cysteine-type endopeptidase activity involved in apoptotic processGO:00431549.9HGF, IL6, VEGFA
31negative regulation of apoptotic processGO:00430669.8FLT4, HGF, IL6, IL6ST, KDR, VEGFA
32positive regulation of cell proliferationGO:00082849.7FGF2, FGF4, FGF5, FLT4, HGF, IL6

Molecular functions related to Kaposi Sarcoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1interleukin-6 bindingGO:001998110.4IL6R, IL6ST
2fibroblast growth factor receptor bindingGO:000510410.2FGF2, FGF5

Sources for Kaposi Sarcoma

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet